Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 124 full-time employees. The company went IPO on 2020-12-04. The company is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. The company has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.
Dr. Omid Farokhzad es el Chairman of the Board de Seer Inc, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción SEER?
El precio actual de SEER es de $1.93, ha disminuido un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Seer Inc?
Seer Inc pertenece a la industria Life Sciences Tools & Services y el sector es Health Care
¿Cuál es la capitalización bursátil de Seer Inc?
La capitalización bursátil actual de Seer Inc es $108.8M
¿Es Seer Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Seer Inc, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta